Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0681
+0.0021 (3.18%)
Oct 28, 2025, 9:30 AM EDT
Provectus Biopharmaceuticals Employees
Provectus Biopharmaceuticals had 6 employees as of December 31, 2024. The number of employees increased by 2 or 50.00% compared to the previous year.
Employees
6
Change (1Y)
2
Growth (1Y)
50.00%
Revenue / Employee
$76,698
Profits / Employee
-$1,060,963
Market Cap
29.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | 2 | 50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 2 | 100.00% |
| Dec 31, 2020 | 2 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
Provectus Biopharmaceuticals News
- 19 days ago - Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy - GlobeNewsWire
- 4 weeks ago - Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer - GlobeNewsWire
- 4 months ago - Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - GlobeNewsWire
- 5 months ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 10 months ago - Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Provectus Biopharmaceuticals GAAP EPS of $0.00, revenue of $0.11M - Seeking Alpha
- 1 year ago - Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call - GlobeNewsWire